Application and demonstration of domestic innovative radiotherapy equipment in precision treatment of cancer" (2018YFC011402) granted to Professor Geng Mingying, radiotherapy clinicians and physicists specializing in nasopharyngeal carcinoma from Chongqing jointly conducted literature research, discussion and consensus letter judgment and reached an evidence‐based consensus at the recommendation level regarding the delineation of lymphatic drainage areas and OARs in IMRT for nasopharyngeal carcinoma. The Chongqing expert consensus on lymphatic drainage areas and OARs in IMRT for nasopharyngeal carcinoma can provide reference for radiotherapy clinicians, thus improving the standardized treatment of nasopharyngeal carcinoma."/>
鼻咽癌IMRT靶区勾画重庆专家共识之淋巴引流区与危及器官
[an error occurred while processing this directive]
Target delineation of lymphatic drainage area and organ at risk in IMRT for nasopharyngeal carcinoma: a Chongqing expert consensus
Digital Medicine of Chinese Medical Association, Radiation Therapy Specialized Committee of Chongqing Medical Association, Radiation Therapy Specialized Committee of Chongqing Association of Integrative Medicine, Radiation Therapy Specialized Committee of Chongqing Anti‐Cancer Association
Abstract：Supported and promoted by the National Key Research & Development Plan of "Application and demonstration of domestic innovative radiotherapy equipment in precision treatment of cancer" (2018YFC011402) granted to Professor Geng Mingying, radiotherapy clinicians and physicists specializing in nasopharyngeal carcinoma from Chongqing jointly conducted literature research, discussion and consensus letter judgment and reached an evidence‐based consensus at the recommendation level regarding the delineation of lymphatic drainage areas and OARs in IMRT for nasopharyngeal carcinoma. The Chongqing expert consensus on lymphatic drainage areas and OARs in IMRT for nasopharyngeal carcinoma can provide reference for radiotherapy clinicians, thus improving the standardized treatment of nasopharyngeal carcinoma.
Digital Medicine of Chinese Medical Association,Radiation Therapy Specialized Committee of Chongqing Medical Association,Radiation Therapy Specialized Committee of Chongqing Association of Integrative Medicine et al. Target delineation of lymphatic drainage area and organ at risk in IMRT for nasopharyngeal carcinoma: a Chongqing expert consensus[J]. Chinese Journal of Radiation Oncology, 2022, 31(12): 1101-1108.
[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. [2] Zhang L, Huang Y, Hong S, et al.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016,388(10054):1883-1892. DOI: 10.1016/S0140-6736(16)31388-5. [3] Lang J, Hu C, Lu T, et al.Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives[J]. Cancer Manag Res, 2019,11:6365-6376. DOI: 10.2147/CMAR.S197544. [4] Lee AW, Ng WT, Pan JJ, et al.International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018,126(1):25-36. DOI: 10.1016/j.radonc.2017.10.032. [5] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会. 中国鼻咽癌放射治疗指南(2020版)[J]. 中华肿瘤防治杂志, 2021,28(3):167-177. DOI:10.16073/j.cnki.cjcpt.2021.03.0. Radiotherapy Oncologist Branch of Chinese Medical Doctor Association, Radiation Oncology Branch of Chinese Medical Association. Radiotherapy guidelines for nasopharyngeal carcinoma in China (2020 edition)[J]. Chin J Cancer Prev Treat, 2021,28(3):167-177. DOI:10.16073/j.cnki.cjcpt.2021.03.0. [6] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志,2011,20(4):267-269. DOI: 10.3760/cma.j.issn.1004-4221.2011.04.001. Chinese Committee for Staging of Nasopharyngeal Carcinoma. Expert consensus on target area and dose design guidelines of intensity modulated radiotherapy for nasopharyngeal carcinoma in 2010[J]. Chin J Radiat Oncol, 2011,20(4):267-269. DOI: 10.3760/cma.j.issn.1004-4221.2011.04.001. [7] 罗京伟,徐国镇,高黎.头颈部肿瘤放射治疗图谱[M].3版.北京:人民卫生出版社,2020. Luo JW, Xu GZ, Gao L.Atlas of radiotherapy for head and neck tumors[M].3rd ed. Beijing: People's Medical Publishing House,2020. [8] Guo QJ, Xiao N, Xu HC, et al.Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the international guideline[J]. Radiother Oncol, 2022,167:239-243. DOI:10.1016/j.radonc.2021.12.032. [9] Poon I, Fischbein N, Lee N, et al.A population-based atlas and clinical target volume for the head-and-neck lymph nodes[J]. Int J Radiat Oncol Biol Phys, 2004,59(5):1301-1311. DOI: 10.1016/j.ijrobp.2004.01.038. [10] Lin L, Lu Y, Wang XJ, et al.Delineation of neck clinical target volume specific to nasopharyngeal carcinoma based on lymph node distribution and the international consensus guidelines[J]. Int J Radiat Oncol Biol Phys, 2018,100(4):891-902. DOI: 10.1016/j.ijrobp.2017.11.004. [11] 王孝深. 鼻咽癌精确放疗的靶区勾画:依据、原则与细节[M].北京:中国科学技术出版社,2021. Wang XS.Target Delineation of Precise Radiotherapy for Nasopharyngeal Carcinoma: Basis, Principle and Details[M]. Beijing: Science and Technology of China Press, 2021. [12] Grégoire V, Ang K, Budach W, et al.Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines[J]. Radiother Oncol, 2014,110(1):172-181. DOI: 10.1016/j.radonc.2013.10.010. [13] Li L, Li Y, Zhang J, et al.Optimization of cervical lymph node clinical target volume delineation in nasopharyngeal carcinoma: a single center experience and recommendation[J]. Oncotarget, 2018,9(43):26980-26989. DOI: 10.18632/oncotarget.23723. [14] Robbins KT, Clayman G, Levine PA, et al.Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery[J]. Arch Otolaryngol Head Neck Surg, 2002,128(7):751-758. DOI: 10.1001/archotol.128.7.751. [15] Robbins KT, Shaha AR, Medina JE, et al.Consensus statement on the classification and terminology of neck dissection[J]. Arch Otolaryngol Head Neck Surg, 2008,134(5):536-538. DOI: 10.1001/archotol.134.5.536. [16] Jiang C, Gao H, Zhang L, et al.Distribution pattern and prognosis of metastatic lymph nodes in cervical posterior to level V in nasopharyngeal carcinoma patients[J]. BMC Cancer, 2020,20(1):667. DOI: 10.1186/s12885-020-07146-z. [17] Jiang C, Gong B, Gao H, et al.Correlation analysis of neck node levels in 960 cases of nasopharyngeal carcinoma (NPC)[J]. Radiother Oncol, 2021,161:23-28. DOI: 10.1016/j.radonc. 2021.05.020. [18] Wang X, Hu C, Ying H, et al.Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels[J]. Radiother Oncol, 2015,115(1):41-45. DOI: 10.1016/j.radonc. 2015.02.017. [19] Robbins KT.Integrating radiological criteria into the classification of cervical lymph node disease[J]. Arch Otolaryngol Head Neck Surg, 1999,125(4):385-387. DOI: 10.1001/archotol.125.4.385. [20] Grégoire V, Levendag P, Ang KK, et al.CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines[J]. Radiother Oncol, 2003,69(3):227-236. DOI: 10.1016/j.radonc.2003.09.011. [21] 柏树令. 系统解剖学[M].7版.北京:人民卫生出版社,2008. Bai SL.Systematic Anatomy[M]. 7th ed. Beijing: People's Medical Publishing House, 2008. [22] Xu Y, Zhang M, Yue Q, et al.Analysis of rare periparotid recurrence after parotid gland-sparing intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Cancer Radiother, 2016,20(5):377-383. DOI: 10.1016/j.canrad. 2016.05.012. [23] Li JG, Venigalla P, Leeman JE, et al.Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma[J]. Laryngoscope, 2017,127(2):377-382. DOI: 10.1002/lary.26139. [24] Wang HZ, Cao CN, Luo JW, et al.High-risk factors of parotid lymph node metastasis in nasopharyngeal carcinoma: a case-control study[J]. Radiat Oncol, 2016,11(1):113. DOI: 10.1186/s13014-016-0691-x. [25] Xu Y, Chen X, Zhang M, et al.Prognostic effect of parotid area lymph node metastases after preliminary diagnosis of nasopharyngeal carcinoma: a propensity score matching study[J]. Cancer Med, 2017,6(10):2213-2221. DOI: 10.1002/cam4. 1154. [26] Zhang Y, Zhang ZC, Li WF, et al.Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: an analysis in 10,126 patients[J]. Oral Oncol, 2019,95:150-156. DOI: 10.1016/j.oraloncology.2019.06.013. [27] 潘伟人. 人体躯干淋巴系统解剖图谱[M]. 北京:人民卫生出版社,2014. Pan WR.Atlas of Lymphatic Anatomical on the Human Trunk[M]. Beijing: People's Medical Publishing House, 2014. [28] Lee AW, Ng WT, Pan JJ, et al.International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019,105(3):567-580. DOI: 10.1016/j.ijrobp.2019. 06.2540. [29] Sun Y, Yu XL, Luo W, et al.Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy[J]. Radiother Oncol, 2014,110(3):390-397. DOI: 10.1016/j.radonc.2013.10.035.
2022, Vol. 31 
